ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Free Report) Director Madge K. Shafmaster bought 60,000 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director now owns 68,333 shares in the company, valued at approximately $85,416.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
ProMIS Neurosciences Stock Up 0.8 %
Shares of NASDAQ PMN opened at $1.31 on Thursday. The business’s 50 day moving average price is $1.39 and its two-hundred day moving average price is $1.71. The company has a market cap of $24.84 million, a PE ratio of -1.77 and a beta of 0.62. ProMIS Neurosciences, Inc. has a twelve month low of $0.95 and a twelve month high of $3.10.
ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. As a group, research analysts anticipate that ProMIS Neurosciences, Inc. will post -0.24 EPS for the current fiscal year.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Recommended Stories
- Five stocks we like better than ProMIS Neurosciences
- There Are Different Types of Stock To Invest In
- Should You Invest in Treasury Bills?
- What is the Hang Seng index?
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- How to Calculate Return on Investment (ROI)
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.